TB/Flu-06E
The vaccine platform is based on the live influenza virus vector that is highly attenuated through alteration in NS1 protein function. This effect is achieved by the replacement of immunosuppressive C-terminal part of NS1 open reading frame with foreign sequences, encoding ESAT-6 antigen of M. tuberculosis. Importantly, viral vector itself acts as an adjuvant, stimulating…
Read MoreMip3a/relMtb
The Mip3a/relMtb vaccine is an intranasal therapeutic DNA fusion vaccine encoding the M. tuberculosis stringent response antigen relMtb (Rv2583c) linked to the immature dendritic cell–targeting chemokine Mip3a/CCL20, formulated as a plasmid DNA construct without an added adjuvant.
Read MoreNETB-EA
The Khader Lab in collaboration with EclipTB Inc andBlueWillow Biologics Inc., have developed an intranasal booster sub-unit, mucosal vaccine comprising of Mtb immunodominant antigens Early secreted antigenic target 6 kDa andAntigen 85B together with nanoemulsion adjuvant NE01-NETB-EA.
Read MoreTBvac-1, TBvac-2, TBvac-10
TBvac-1, TBvac-2, and TBvac-10 use a recombinant tri-segmented Pichinde virus (PICV) vector (rP18tri) to express M. tuberculosis antigens. TBvac-1 and TBvac-2 encode Ag85B, EsxA/ESAT-6, and EsxH/TB10.4, with antigen locations swapped between S1 and S2 segments. TBvac-10 encodes Ag85B, EsxH/TB10.4, RpfA, and Rv1733c. Vaccine stocks are produced in BHK-21 cells from plaque purified virus.
Read MoreBCG-EVs
This vaccine comprises EVs derived from Mycobacterium bovis and Escherichia coli Nissle 1917. BCG-EVs carry multiple molecules, including known protective TB antigens. The EVs will be lyophilized to ensure physicochemical stability and eliminate the need for a cold chain. Owing to their acellular nature, the vaccine is suitable for infants and children, including those living…
Read More